Chiron, Roche Settle HCV/HIV Patent Dispute Via $115 Mil. Licensing Pact
This article was originally published in The Gray Sheet
Executive Summary
A licensing agreement struck between Chiron and Roche, announced Oct. 11, resolves patent litigation pending against Roche in the U.S. and overseas related to probe-based hepatitis C virus (HCV) and HIV clinical diagnostics while leaving intact complaints against Roche in Germany related to antibody-based HCV immunoassay diagnostic patents.
You may also be interested in...
Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap
Chugai's decision to spin off its wholly-owned diagnostic subsidiary Gen-Probe following a merger with Roche's Japanese unit, Nippon Roche, will preserve worldwide competition between Roche's Cobas AmpliScreen nucleic acid test (NAT) line and Chiron's Procleix NAT, developed with Gen-Probe
Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap
Chugai's decision to spin off its wholly-owned diagnostic subsidiary Gen-Probe following a merger with Roche's Japanese unit, Nippon Roche, will preserve worldwide competition between Roche's Cobas AmpliScreen nucleic acid test (NAT) line and Chiron's Procleix NAT, developed with Gen-Probe
Bayer HCV/HIV Lab Tests Anticipated In 2002 Via Chiron/Ortho License
Bayer immunodiagnostic lab tests for hepatitis C and HIV antibodies are expected to roll out by the end of 2002 for use on the firm's existing Advia Centaur automated immunoassay system.